Skip to main content
logo
Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
30.42
-0.25 (-0.82%)
Nov 3, 2026, 2:05 PM EST - Market open

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Period Ending
Sep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20
Primary Care Revenue
6.97B
Oncology Revenue
4.33B
Specialty Care Revenue
3.35B
Hospital and Biosimilars Revenue
1.64B
Global Pharmaceuticals Business (Biopharma) Revenue
16.28B
Business Innovation (Pfizer CentreOne) Revenue
300.00M
Revenue (Other)
-
Revenue (Total)
16.58B

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Period Ending
Sep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20
United States Revenue
10.60B
Developed Markets Revenue
3.64B
Emerging Markets Revenue
2.34B
Revenue (Other)
1.00M
Revenue (Total)
16.58B

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Period Ending
Sep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20
United States Revenue
10.60B
Revenue (Total)
16.58B

Revenue by Geography 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Period Ending
Sep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20
United States Revenue
10.60B
International Revenue
5.98B
Revenue (Total)
16.58B

EBT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Period Ending
Sep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20
Global Pharmaceuticals Business (Biopharma) Earnings
8.24B
Other Business Activities Earnings
-2.44B

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter
Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021Q1 2021Q4 2020
Period Ending
Sep '26 Jun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Oct '23 Jul '23 Apr '23 Dec '22 Oct '22 Jul '22 Apr '22 Dec '21 Oct '21 Jul '21 Apr '21 Dec '20
Comirnaty - Direct Sales and Alliance Revenue
808.00M
Eliquis - Direct Sales and Alliance Revenue
2.52B
Paxlovid Revenue
449.00M
Prevnar Family Revenue
1.56B
Nurtec ODT/Vydura Revenue
547.00M
Abrysvo Revenue
303.00M
Vyndaqel Family Revenue
1.77B
Xeljanz Revenue
213.00M
Ibrance Revenue
1.08B